MA27746A1 - VACCINES - Google Patents

VACCINES

Info

Publication number
MA27746A1
MA27746A1 MA28489A MA28489A MA27746A1 MA 27746 A1 MA27746 A1 MA 27746A1 MA 28489 A MA28489 A MA 28489A MA 28489 A MA28489 A MA 28489A MA 27746 A1 MA27746 A1 MA 27746A1
Authority
MA
Morocco
Prior art keywords
muc
relates
vaccines
recombinant
dnas
Prior art date
Application number
MA28489A
Other languages
French (fr)
Inventor
Paul Andrew Hamblin
Del Cura Maria De Los An Rocha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27746A1 publication Critical patent/MA27746A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux ADN MUC-1 recombinés, qui présentent une homologie réduite avec le MUC-1 naturel. L'invention concerne également des compositions pharmaceutiques contenant de tels MUC-1 recombinés.The invention relates to novel recombinant MUC-1 DNAs which exhibit reduced homology with natural MUC-1. The invention also relates to pharmaceutical compositions containing such recombinant MUC-1.

MA28489A 2003-02-28 2005-09-09 VACCINES MA27746A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0304634.9A GB0304634D0 (en) 2003-02-28 2003-02-28 Vaccines

Publications (1)

Publication Number Publication Date
MA27746A1 true MA27746A1 (en) 2006-02-01

Family

ID=9953871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28489A MA27746A1 (en) 2003-02-28 2005-09-09 VACCINES

Country Status (18)

Country Link
US (1) US20060147458A1 (en)
EP (1) EP1597368A2 (en)
JP (1) JP2007524352A (en)
KR (1) KR20050107472A (en)
CN (1) CN1753994A (en)
AU (1) AU2004215187A1 (en)
BR (1) BRPI0407601A (en)
CA (1) CA2517062A1 (en)
CO (1) CO5670372A2 (en)
GB (1) GB0304634D0 (en)
IS (1) IS7956A (en)
MA (1) MA27746A1 (en)
MX (1) MXPA05009160A (en)
NO (1) NO20054102L (en)
PL (1) PL378761A1 (en)
RU (1) RU2005125608A (en)
WO (1) WO2004076665A2 (en)
ZA (1) ZA200506548B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
CN103570821A (en) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 Mucin-1 antigenic polypeptide and application thereof as tumor vaccine
WO2018060368A2 (en) 2016-09-28 2018-04-05 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
CN113321724B (en) * 2021-03-24 2022-02-01 深圳市新靶向生物科技有限公司 Antigenic peptide related to esophageal cancer driver gene mutation and application thereof
WO2023122526A1 (en) * 2021-12-20 2023-06-29 Zoetis Services Llc Use of interferon as an adjuvant in vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DK1210430T3 (en) * 1999-09-08 2006-11-20 Transgene Sa MUC-1-derived peptides
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
ZA200506548B (en) 2007-12-27
BRPI0407601A (en) 2006-02-14
WO2004076665A3 (en) 2005-02-24
GB0304634D0 (en) 2003-04-02
US20060147458A1 (en) 2006-07-06
RU2005125608A (en) 2006-03-27
EP1597368A2 (en) 2005-11-23
AU2004215187A1 (en) 2004-09-10
CA2517062A1 (en) 2004-09-10
PL378761A1 (en) 2006-05-15
MXPA05009160A (en) 2005-10-20
IS7956A (en) 2005-07-25
CO5670372A2 (en) 2006-08-31
NO20054102L (en) 2005-09-27
NO20054102D0 (en) 2005-09-02
KR20050107472A (en) 2005-11-11
WO2004076665A2 (en) 2004-09-10
CN1753994A (en) 2006-03-29
JP2007524352A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
MA29413B1 (en) COMBINATIONS OF ACTIVE SUBSTANCES
YU9404A (en) Peptide-based multimeric targeted contrast agents
DE60228219D1 (en) ALCOHOL BURNER
MA30581B1 (en) RECOMBINANT VIRAL VACCINE
YU19903A (en) Novel receptor nucleic acids and polypeptides
DK1117440T3 (en) Pharmaceutical compositions containing paclitaxel
EP1554301A4 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
WO2003015697A3 (en) Interleukin-2 mutants with reduced toxicity
MA29459B1 (en) VACCINES
IL151313A0 (en) Lipase containing pharmaceutical compositions
UA91815C2 (en) Isolated antibody that specifically binds to gdf-8 and use thereof
WO2004024757A3 (en) Modified pna molecules
WO2001064835A8 (en) Novel nucleic acids and polypeptides
MA27746A1 (en) VACCINES
EA200800698A1 (en) METHOD FOR STABILIZATION OF PHARMACEUTICAL FORMS FOR INTRODUCTION INCLUDING MICROORANISM
AU8738401A (en) Novel kallikrein gene
DE60216305D1 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL COMBINATIONS
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
DE50204688D1 (en) N-ALKYLAZIRIDINOPREPOLYMERS AS DENTAL MASS
EA200600403A1 (en) KLADRIBIN PREPARATIONS FOR IMPROVED ORAL DELIVERY AND DELIVERY THROUGH SLEDGE SHELLS
MXPA03009478A (en) Impact resistant modified blends made of polyethylenterephthalate and at least one polycarbonate based on dihydroxydiarylcyclohexane.
ATE473283T1 (en) DNA EXPRESSION VECTORS
PL1622939T3 (en) Active variants of the il-18 binding protein and medical uses thereof
ITRM20050064A1 (en) POLIEPITOPIC PEPTIDE DERIVED FROM TIMIDILATO SINTETASI WITH IMMUNOLOGICAL AND ANTITUMORAL ACTIVITY AND RELATIVE PHARMACEUTICAL COMPOSITIONS.
PL1677818T3 (en) Stable aqueous g-csf-containing compositions